Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia Meeting Abstract


Authors: Schiller, G. J.; Tallman, M. S.; Goldberg, S. L.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Larson, R. A.; Russell, N.; Trone, D.; Gammon, G.; Levis, M. J.; Cortes, J. E.
Abstract Title: Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613203917
PROVIDER: wos
Notes: Meeting Abstract: 7100 -- Source: Wos
MSK Authors
  1. Martin Stuart Tallman
    408 Tallman